[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@financebully Avatar @financebully financebully

financebully posts on X about $ptgx, $jnj, $nams, $5b the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXX% finance XXX% cryptocurrencies XXXX% technology brands XXXX%

Social topic influence $ptgx #30, $jnj 2.21%, $nams 1.66%, $5b 1.1%, $mrna 1.1%, $iobt 1.1%, $hrmy 1.1%, $75sh #1, $idya 1.1%, $kura XXXX%

Top accounts mentioned or mentioned by @wallstsai @pjamess69 @semodough @doepkemichel @tradingsssss @hothomaswphelps @madrigalpharma @houndcl @bioinvestor24 @adamfeuerstein @jabroni16 @pfizer @jfais20 @cjkb117 @avidresearch @grok @goldmansachs @bananaoncology @bambossie81 @badinvestor99

Top assets mentioned Protagonist Therapeutics, Inc (PTGX) Johnson & Johnson (JNJ) NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Moderna Inc (MRNA) IDEAYA Biosciences, Inc. Common Stock (IDYA) Acadia Pharmaceuticals Inc. (ACAD) Cardano (ADA) Ethereum (ETH) Polygon (MATIC) GSK plc (GSK) Synthetify (SNY) Insmed, Inc. (INSM)

Top Social Posts #

Top posts by engagements in the last XX hours

"@semodough should definitely be larger than a $5b+ opportunity. hope they're not trying to down play the $$ potential to support negotiations w/ $ptgx"
X Link @financebully 2025-10-14T14:14Z XXX followers, XXX engagements

"@jfais20 $kura ev is only $250m w/ a likely upcoming lead asset approval which would trigger additional milestone payments. i'm sticking with this one. glta"
X Link @financebully 2025-10-15T11:26Z XXX followers, XXX engagements

"@JacobPlieth $evax data will also be interesting to watch out for. personalized like $mrna (mrna-4157) but peptide-based like $iobt"
X Link @financebully 2025-10-13T14:40Z XXX followers, XXX engagements

"@SteveWagsInvest @DeepSouthDoctor @HarmonyBio i am partially kidding around. i actually have liked both $hrmy and $acad in the neuro space given their existing products/revenues as well as remaining pipelines despite upcoming competition. but the selling activity of the ceo and cfo + ph3 fxs fail have rocked my confidence"
X Link @financebully 2025-10-13T16:03Z XXX followers, XXX engagements

"@adamfeuerstein even crazier is that the current ceo of monopar originally developed the drug as an undergrad at northwestern. he founded the company (wilson therapeutics) that was acquired by alexion (then by az). then the drug was later licensed by monopar back in the hands of developer"
X Link @financebully 2025-10-09T11:39Z XXX followers, 1510 engagements

"@doepke_michel @pnani456 and $ptgx bod would be foolish to sell the entire company for below $5b ($75/sh). $ptgx remaining financial interest in icotrokinra alone will conservatively be close to $750m/year by 2030. jnj's $5b pys is way too low"
X Link @financebully 2025-10-13T18:00Z XXX followers, XXX engagements

"$nams for patients with very high cardiovascular risk who require additional ldl-c reduction beyond what statins and other therapies can provide obicetrapib offers a promising oral option. independent meta-analysis recently published"
X Link @financebully 2025-09-26T15:50Z XXX followers, XXX engagements

"@doepke_michel this seems more believable that $jnj would pay $75/sh for rest of icotrokinra (+ pipeline asset maybe) then leave the rest or spinout a new company w/ shareholders getting shares in the new company. this would be fair - although new company may be valued at $1-2b"
X Link @financebully 2025-10-13T18:46Z XXX followers, XXX engagements

"$idya looks to be on par with zai lab zl-1310 but impressive nonetheless. 💥"
X Link @financebully 2025-09-07T15:39Z XXX followers, 1517 engagements

"@pnani456 @doepke_michel $jnj unlikely would announce any deal prior to er (quiet period)"
X Link @financebully 2025-10-13T17:32Z XXX followers, XXX engagements

"@ohadhammer unique many are either late stage and/or me2s (3x fgf21 glp1)"
X Link @financebully 2025-10-14T23:11Z XXX followers, XXX engagements

"@doepke_michel unlikely entirely true. unlikely that $jnj would use blackstone as their ib"
X Link @financebully 2025-10-13T17:27Z XXX followers, XXX engagements

"@bitcollectr The better question is why $ADA has a market cap of $90Bn while $ETH and $MATIC MCs are $390Bn and $10.5Bn No reason beyond cult community with disposable income to spend. I have a bag of $ada but dont think its worth the current valuation. Itll correct"
X Link @financebully 2021-08-23T13:05Z XXX followers, XX engagements

"@avidresearch would be a smart move for $mrna or better yet $bntx acquired $iobt. they have the cash/resources to redo the ph3 quickly"
X Link @financebully 2025-10-13T14:08Z XXX followers, 1278 engagements

"@herostick $25m (including wind down costs) vs $30m (near term milestones) seems like a big win for this company/molecule. not sure why $gsk doesn't just acquire $scyx ($34m mc -$8m ev) at this point though. $150-200m and they're done"
X Link @financebully 2025-10-15T13:18Z XXX followers, XXX engagements

"@PersimmonTI i'm not sure if they will be the next but i've been bullish on $nams for several months now after broadway study suggested mace benefit and more recently the ptau217 data. huge added benefit over other treatments in the space. + very strong team/bod"
X Link @financebully 2025-10-13T14:53Z XXX followers, XXX engagements

"@webcrawler_vers @seedy19tron @Biotenic never a guarantee which is what wsj also says. again it was pretty easy to realize that there was a no guarantee high probability that either $jnj or $tak would want to acquire $ptgx after the clinical success of the two drugs"
X Link @financebully 2025-10-13T13:53Z XXX followers, XXX engagements

"@HarmonyBio $hrmy execs have no confidence in the company"
X Link @financebully 2025-10-11T17:00Z XXX followers, XX engagements

"interesting that biox hasn't been chatting about $sabs. regardless of what you think about approach or market (s3 t1d) the company closed a $175m priv plac in july w/ $sny racap vivo et al participating. at $27m mc (-$140m) this appears undervalued and a good investment"
X Link @financebully 2025-09-18T11:04Z XXX followers, 1192 engagements

"@haodongvli $insm is overvalued atm so i'd be surprised if they could find a buyer. i think it would be wise for $ptgx to sell as long as its a fair value of not just their lead programs but also their clinically validate platform and pipeline"
X Link @financebully 2025-10-13T20:16Z XXX followers, XXX engagements

"$idya. great r&d day and company"
X Link @financebully 2025-09-08T13:47Z XXX followers, 1654 engagements

"@AnotherBio JNJ-89853413 also remains active/recruiting as of update on Oct XX. $lvtx"
X Link @financebully 2025-10-12T18:39Z XXX followers, XXX engagements

"@PersimmonTI this meta-analysis of prior ph3 studies bodes well for likelihood of prevail sucess. $nams"
X Link @financebully 2025-10-13T14:58Z XXX followers, XXX engagements